



5710

PURGED *PAK*

Food and Drug Administration
Minneapolis District
240 Hennepin Avenue
Minneapolis MN 55401-1999
Telephone: 612-334-4100

February 12, 2001

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Refer to MIN 01 - 31

Gregory K. Britton
President and Chief Executive Officer
Beloit Memorial Hospital
1969 West Hart Road
Beloit, Wisconsin 53511

Dear Mr. Britton:

On January 23, 2001, a representative of the State of Wisconsin, acting on behalf of the Food and Drug Administration (FDA), inspected your facility (FDA mammography certificate #164756). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992 (MQSA), your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. Based on the documentation your site presented at the time of the inspection, the following findings were documented at your facility:

Repeat Level 2 Non-Compliance:

1. One of seven randomly selected mammography reports either lacked an assessment category or the assessment category did not meet either the official or approved alternate wording for assessment categories. This was also cited during the previous inspection.

Level 2 Non-Compliance:

2. Phantom QC records (a mandatory weekly test) were missing for two weeks. (Evaluation criteria is number of weeks missing in worst 12-week interval.)

Page Two

Gregory K. Britton
February 12, 2001

Repeat Level 3 Non-Compliance:

3. The required personnel documents were unavailable during the inspection. This was also cited during the previous inspection.

Your site must ensure that mammography personnel met minimum standards **prior** to allowing any person to perform mammography at your site. This can only be assured by your site's review of their appropriate supporting documentation. MQSA inspections, by FDA policy, are pre-announced. This policy allows for possible patient rescheduling, but also affords the site an opportunity to ensure that the appropriate records are available to the inspector on the day of the inspection.

The specific problems noted above appeared on your MQSA Facility Inspection Report which was issued to your facility following the close of the inspection.

Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within 15 working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures if the findings relate to quality control or other records.

Please submit your response to Thomas W. Garvin, Radiological Health Specialist, Food and Drug Administration, 2675 No. Mayfair Road, Suite 200, Milwaukee, WI 53226-1305.

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does

Page Three

Gregory K. Britton
February 12, 2001

not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov/cdrh/mammography/index.html>.

If you have specific questions about mammography facility requirements or about the content of this letter please feel free to phone Mr. Garvin at (414) 771-7167 ext. 12.

Sincerely,


James A. Raito
Director
Minneapolis District

CAH TWG/ccl

xc: 
Lead Interpreting Radiologist
Beloit Memorial Hospital
1969 West Hart Road
Beloit, WI 53511

Paul Schmidt
Chief, Radiation Protection Unit
State of Wisconsin
P.O. Box 2659
Madison, WI 53701-2659

Priscilla F. Butler
Director, Breast Imaging Accreditation Programs
American College of Radiology
1891 Preston White Drive
Reston, VA 20191